Navigation Links
MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
Date:1/10/2012

KENNESAW, Ga., Jan. 10, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has received the certification for the Company's proprietary CollaFix™ Surgical Mesh CD.  This certification of CollaFix™ Surgical Mesh CD, which is a Class III product in Europe, was issued by the Company's notified body, AMTAC Certification Services, Limited, based in the United Kingdom.

This certification is the first for the Company's CollaFix™ platform technology.

Parker H. "Pete" Petit, Chairman and CEO commented, "We are very pleased to receive our first regulatory certification for our unique CollaFix™ technology.  Our collagen fibers, that are the size of human hair, are fabricated in continuous lengths and have similar strength and stiffness to human tendons.  The fibers are bio-compatible and resorbable.  We expect this certification to be the first of many in a line of products using our CollaFix™ technologies to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair."

CollaFix™ Surgical Mesh CD has not been cleared for use in the United States.

About the Company

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix®, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane,
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MiMedx Group Announces Temporary Trading Symbol Designation
2. MiMedx Group, Inc. to Present at Noble Financial Sixth Annual Equity Conference
3. MiMedx Group, Inc. Announces Release Date For Third Quarter Results
4. MiMedx Group, Inc. to Present at the 13th Annual Needham Growth Conference
5. MiMedx to Attend American Academy of Orthopedic Surgeons Annual Meeting
6. MiMedx Announces Launch of AmnioFix™
7. MiMedx Group, Inc. to Present at the 10th Annual Needham Healthcare Conference
8. MiMedx Group Announces 2010 Results
9. MiMedx Group Announces First Quarter 2011 Results
10. MiMedx Group, Inc. to Present at the Noble Financial Capital Markets Seventh Annual Equity Conference
11. MiMedx Group Completes $5,000,000 Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 6, 2015 ... von der Assistance Publique - Hôpitaux de ... ist eine französische, gemeinschaftliche, randomisierte Kontrollstudie für ... wurden. Verglichen werden Patienten mit fortgeschrittenem hepatozellulärem ... oder Sorafenib behandelt wurden. Die Ergebnisse werden ...
(Date:3/5/2015)... --  HX360 today announced that sixteen companies have ... Challenge competition. These companies, selected from a field ... one of four finalists to present their solutions live ... venture capitalists during the Innovation Challenge event. ... 2015 HIMSS Annual Conference & Exhibition, McCormick Place in ...
(Date:3/5/2015)... 05, 2015 BioPlus Specialty Pharmacy (BioPlus) ... of Vice President of Managed Care. In this role, ... one of the nation’s leading specialty pharmacies. , Damm, ... years of specialty pharmacy and biotech experience to his ... Pharmaceuticals, Vertex Pharmaceuticals, and Pfizer. Prior to working in ...
(Date:3/5/2015)... and TORONTO , March ... APS), a clinical-stage company developing new therapeutics and molecular ... announced that William G. Rice , Ph.D., Chairman, ... upcoming 27th Annual ROTH Conference on Tuesday, March 10 ... Ritz Carlton, Laguna Niguel, CA. ...
Breaking Biology Technology:Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3
... that Dr. Robert Harman, DVM, MPVM, CEO of Vet-Stem, ... of Action" at the Annual Research Symposium of the ... October 21, 2010.   (Logo: http://photos.prnewswire.com/prnh/20060425/VETSTEMLOGO ... Dr. Harman has presented at more than 40 veterinary ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, ... for its CYT387 JAK1/JAK2 inhibitor program demonstrating that ... profile which may provide significant clinical advantages. CYT387 ... clinical study at Mayo Clinic in patients with ...
... RALEIGH, NC and QUEBEC CITY, Oct. 1 /PRNewswire-FirstCall/ ... of Medicago Inc. (TSX: MDG), a biotechnology company ... based on proprietary manufacturing technologies and Virus-Like Particles ... U.S. Senator Kay Hagan (D-NC) and U.S. Congressman ...
Cached Biology Technology:Vet-Stem CEO to Present Invited Talk at Veterinary Surgery Meeting 2YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference 2YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference 3Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 2Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 3
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... N.C. , Feb. 5, 2015  Marken is ... logistics company and has launched a new marketing campaign ... Logistics Organization (CLO).  The new campaign focuses on ... patient, protocol and shipments. The first headline ... , aligns Marken,s priorities with its client,s priorities. Marken ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces the ... as part of its 2015 marketing and branding initiatives ... new consumer website for Wocketwallet.com earlier this month. ... said, "Our new corporate website naturally showcases our premiere ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... time, researchers have inhibited the development of epilepsy after a ... signaling pathways in the brain, neurology researchers found that they ... , "We have shown that there is a window ... that epilepsy will develop," said one of the lead researchers, ...
... Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ... that a single drug can rebuild damaged muscle in ... two human forms of muscular dystrophy. This advance, which ... from a research collaboration that began several years ago ...
... What is more, a newt can also completely repair damage ... Heart and Lung Research in Bad Nauheim have now started ... regenerate and have discovered the remarkable plasticity of newt heart ... this ability, the findings could contribute to new cell therapies ...
Cached Biology News:Gene therapy inhibits epilepsy in animals 2Scientists show drug can counteract muscular dystrophy in mice 2Newts which regrow their hearts 2
... DNA Polymerase I from ... DNA polymerase. The enzyme also ... activities.1 The 5'?3' exonuclease activity ... nicks and gaps in the ...
... E. coli strain containing an overproducing clone ... Reverse Transcriptase catalyzes the polymerization of DNA ... Full-length copies of large mRNAs, >10 kb, ... a much lower RNase H activity than ...
... catalyzes the template-directed polymerization of nucleotides into ... Polymerase I possesses a 3?5 exonuclease activity ... rate during DNA replication, and also contains ... enzyme to replace nucleotides in the growing ...
Request Info...
Biology Products: